CasNo.38226-86-7,Anhydroicaritin 38226-86-7,(38226-86-7) Suppliers

5 Kilogram	FOB Price:USD 45.0000 -65.0000

Min.Order :5 Kilogram
Purity: >99%
Payment Terms : L/C,D/A,D/P,T/T

Keywords

Cycloicaritin Anhydroicaritin Icaritin, b-anhydro-

Quick Details

Appearance:Yellow crystalline powder
Application:Cytosine (C) is one of the four main bases found in DNA and RNA, along with adenine, guanine, and thymine (uracil in RNA). Cytosine reagent is used in a wide variety of research applications, as an
PackAge:Brown vial or HDPE plastic bottle
ProductionCapacity:3000|Kilogram|Month
Storage:Cool Dry Place
Transportation:Bag or Drum

Superiority:

OEM Supply Superior Quality 99% Cytosine CAS 71-30-7

Basic Information:

Cytosine (C) is one of the four main bases found in DNA and RNA, along with adenine, guanine, and thymine (uracil in RNA).

Cytosine reagent is used in a wide variety of research applications, as an enzyme-substrate or precursor of effector molecules such as cytosine sugars.

Product Name:	Cytosine
Synonyms:	4-AMINO-2(1H)-PYRIMIDINONE;4-AMINO-2(1)-PYRIMIDONE;4-AMINO-2-PYRIMIDINOL;4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDINE;4-AMINO-2-HYDROXYPYRIMIDINE;2-Oxy-4-amino pyrimidine;AURORA KA-682;CYTOSINE
CAS:	71-30-7
MF:	C4H5N3O
MW:	111.1

Details:

Molecular Formula	C21H20O6
Molar Mass	368.38
Density	1.359
Melting Point	239℃
Boling Point	582.0±50.0 °C(Predicted)
Flash Point	206.7℃
Solubility	DMSO : 14 mg/mL (38.00 mM; Need ultrasonic and warming);H2O : < 0.1 mg/mL (insoluble)
Vapor Presure	3.82E-14mmHg at 25°C
Appearance	Yellow crystalline powder
Color	light yellow to dark yellow
Maximum wavelength(λmax)	368nm(MeOH)(lit.)
pKa	6.44±0.40(Predicted)
Storage Condition	2-8°C
Refractive Index	1.656
MDL	MFCD22422519
Physical and Chemical Properties	Yellow crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from epimedium.
In vitro study	Icaritin (4-64 µM; 48 hours; K562, imatinib-resistant cells and primary CML cells) treatment inhibits proliferation of K562, imatinib-resistant cells and primary CML cells . Icaritin (0-64 µM; 48 hours; K562 and primary cells) treatment induces K562 or primary cells apoptosis in an concentration dependent manner. Icaritin (32 µM; K562 cells) treatment increases cell population in the sub-G1 phase in K562 cells. Icaritin (0-64 µM; 48 hours; K562 cells) treatment inhibits MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression. Icaritin treatment also significantly inhibits Bcl-2 protein expression and up-regulated Bax protein expression in K562 with a dose-dependent manner accompanied by the cleavage activation of caspase-3 or caspase-9, and a down-regulated expression of Apaf-1. Cell Proliferation Assay Cell Line: K562, imatinib-resistant cells and primary CML cells Concentration: 4 µM, 8 µM, 16 µM, 32 µM and 64 µM Incubation Time: 48 hours Result: Inhibited cell proliferation. Apoptosis Analysis Cell Line: K562 or primary cells Concentration: 0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM Incubation Time: 48 hours Result: Induced K562 or primary cells apoptosis. Cell Cycle Analysis Cell Line: K562 cells Concentration: 32 µM Incubation Time: Result: Cell population in the sub-G1 phase was increased. Western Blot Analysis Cell Line: K562 cells Concentration: 0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM Incubation Time: 48 hours Result: Inhibited MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression.
In vivo study	Icaritin (4-8 mg/kg; intraperitoneal injection; daily; for 10 weeks; female NOD-SCID nude mice) treatment could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow in mouse leukemia model. Animal Model: Female NOD-SCID nude mice (6-8 weeks old) with K562 cells Dosage: 4 mg/kg and 8 mg/kg Administration: Intraperitoneal injection; daily; for 10 weeks Result: Could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow.